LIPOSOME COMPANY, LIPOSOME TECHNOLOGY PLANNED MERGER IS OFF
Executive Summary
LIPOSOME COMPANY, LIPOSOME TECHNOLOGY PLANNED MERGER IS OFF; the combination would have created a single corporation named Liposome Companies. In a May 24 press release, the companies announced their "decision to terminate their previously announced merger agreement." The companies originally announced the definitive merger agreement on Feb. 13. At the time, the merger between the oldest liposome R&D firms -- both were founded in 1981 -- was heralded as the beginning of a possible trend of consolidation among existing biotechnology companies. The merger was canceled despite a good fit between the companies' respective research efforts. In the only instances of overlap, both are developing liposomal formulations of the antifungal amphotericin B and doxorubicin; however, the companies have not entered into competing partnership agreements for those products.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth